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The C-X-C motif chemokine ligand 17 (CXCL17) is chemotactic for myeloid cells, exhibits
bactericidal activity, and exerts anti-viral functions. This chemokine is constitutively
expressed in the respiratory tract, suggesting a role in lung defenses. However, little is
known about the participation of CXCL17 against relevant respiratory pathogens in
humans. Here, we evaluated the serum levels and lung tissue expression pattern of
CXCL17 in a cohort of patients with severe pandemic inﬂuenza A(H1N1) from Mexico City.
Peripheral blood samples obtained on admission and seven days after hospitalization
were processed for determinations of serum CXCL17 levels by enzyme-linked
immunosorbent assay (ELISA). The expression of CXCL17 was assessed by
immunohistochemistry (IHQ) in lung autopsy specimens from patients that succumbed
to the disease. Serum CXCL17 levels were also analyzed in two additional comparative
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cohorts of coronavirus disease 2019 (COVID-19) and pulmonary tuberculosis (TB)
patients. Additionally, the expression of CXCL17 was tested in lung autopsy specimens
from COVID-19 patients. A total of 122 patients were enrolled in the study, from which 68
had pandemic inﬂuenza A(H1N1), 24 had COVID-19, and 30 with PTB. CXCL17 was
detected in post-mortem lung specimens from patients that died of pandemic inﬂuenza A
(H1N1) and COVID-19. Interestingly, serum levels of CXCL17 were increased only in
patients with pandemic inﬂuenza A(H1N1), but not COVID-19 and PTB. CXCL17 not only
differentiated pandemic inﬂuenza A(H1N1) from other respiratory infections but showed
prognostic value for inﬂuenza-associated mortality and renal failure in machine-learning
algorithms and regression analyses. Using cell culture assays, we also identiﬁed that
human alveolar A549 cells and peripheral blood monocyte-derived macrophages increase
their CXCL17 production capacity after inﬂuenza A(H1N1) pdm09 virus infection. Our
results for the ﬁrst time demonstrate an induction of CXCL17 speciﬁcally during pandemic
inﬂuenza A(H1N1), but not COVID-19 and PTB in humans. These ﬁndings could be of
great utility to differentiate inﬂuenza and COVID-19 and to predict poor prognosis specially
at settings of high incidence of pandemic A(H1N1). Future studies on the role of CXCL17
not only in severe pandemic inﬂuenza, but also in seasonal inﬂuenza, COVID-19, and PTB
are required to validate our results.
Keywords: inﬂuenza A(H1N1), SARS-CoV-2, COVID-19, tuberculosis, chemokines, CXCL17

death. Finally, we identiﬁed that human alveolar A549 cells
and peripheral blood monocyte-derived macrophages produce
CXCL17 after an in vitro exposure to the inﬂuenza A(H1N1)
pdm09 virus.
Our data might be helpful for the clinical decision-making
process during the ongoing ﬂu season, which is projected to be
one of the most challenging public health crises in recent history
due to the convergence of inﬂuenza and COVID-19. Moreover,
our results for the ﬁrst time indicate that CXCL17 might have a
prognostic value during severe pandemic inﬂuenza A(H1N1).
Overall, these preliminary data justify future efforts to address a
possible role for CXCL17 during inﬂuenza. Also, future studies
on the role of CXCL17 in COVID-19 and PTB are warranted.

INTRODUCTION
The C-X-C motif chemokine ligand 17 (CXCL17) is a mucosal
chemokine expressed in the respiratory tract under both homeostatic
and inﬂammatory conditions (1–3). Its homeostatic functions
include the recruitment of various myeloid cell populations
[dendritic cells (DCs), monocytes, and macrophages] to mucosal
tissues, including the lung (4). Under inﬂammatory conditions, its
functions are less well characterized, although it has been reported to
promote anti-inﬂammatory activities and likely prevent autoimmunity
(2, 4). CXCL17 also exhibits broad antimicrobial activity (2, 4),
suggesting that it may play an important role in protective immunity
against respiratory pathogens. In viral infections, there is only a
report suggesting that CXCL17 participates in immunity against
genitourinary herpes infections (5). However, despite CXCL17 being
one of the most highly expressed chemokines in the human lung, its
potential role in human respiratory infections has not been studied.
Here, we report high levels of CXCL17 in serum from patients
with acute respiratory distress syndrome (ARDS) associated with
pandemic inﬂuenza A(H1N1). Conversely, serum CXCL17 levels
in severely ill coronavirus disease 2019 (COVID-19) patients and
individuals with pulmonary tuberculosis (PTB) were not
elevated, indicating that CXCL17 serum levels are a speciﬁc
diagnostic marker that differentiate pandemic inﬂuenza A
(H1N1) from other infections in patients with respiratory
illness. We also analyzed the pattern of expression of this
chemokine in lung specimens from patients with inﬂuenza and
COVID-19. Importantly, analyses of CXCL17 serum levels in
inﬂuenza A (H1N1) patients revealed that high levels of CXCL17
correlated with poor prognosis, including kidney injury and
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MATERIALS AND METHODS
Study Design and Participants
We conducted a cohort study in hospitalized patients (N = 68)
with laboratory-conﬁrmed inﬂuenza A(H1N1)pdm09 virus
infection (hereinafter referred to as inﬂuenza) that attended
the emergency department of the National Institute for
Respiratory Diseases (INER) of Mexico during the 2018/19 and
2019/20 ﬂu seasons. Patients with inﬂuenza-like illness (ILI) that
progressed to ARDS requiring mechanical ventilation (MV) and
admission to the intensive care unit (ICU) were eligible. These
subjects were screened for inﬂuenza using a rapid inﬂuenza
diagnostic test (RIDT; Fuji dri-chem immuno AG cartridge
FluAB kit, Fujiﬁlm Corp, Tokyo, Japan) in fresh respiratory
swab specimens. Simultaneously, further molecular
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characterization of the causative inﬂuenza virus subtype was
assessed by RT-PCR, as previously described (6).
In addition, we included a group of patients with COVID-19
(N = 24) that attended INER or the National Institute of Medical
Sciences and Nutrition (INCMNSZ) in Mexico City, from March
to May of 2020. The infection with SARS-CoV-2 was detected by
RT-PCR, as described below (7). We also enrolled a third cohort
of individuals with active PTB (N = 30) recruited at the
“Tuberculosis Clinic” of the INER in Mexico City. The
diagnosis of PTB was performed by direct clinical examination,
radiological evaluation, and microbiological analyses of sputum
specimens, as described before (8). None of the patients enrolled
in the study had human immunodeﬁciency virus (HIV)
infection. We retrieved clinical and demographic data from the
participants. Peripheral blood samples were taken from each
patient within the ﬁrst 24 h following hospital admission to
determine serum CXCL17 levels. An additional blood sample
was obtained from patients with inﬂuenza seven days after
admission. Healthy volunteer individuals (N = 30) were also
recruited to participate in the study and served as controls.

saline (PBS). Media containing the inﬂuenza virus was
replaced with a virus-free culture medium. Supernatants were
collected after 24, 48, and 72 h, for CXCL17 quantitation.

CXCL17 Levels
Levels of CXCL17 in human serum and culture supernatants
were determined by enzyme-linked immunosorbent assay
(ELISA) using a commercial kit (MBS916471, My BioSource,
USA) following the manufacturer’s instructions.

Histological Analysis and
Immunohistochemistry
Formalin-ﬁxed and parafﬁn-embedded lung autopsy specimens
from patients who died of inﬂuenza or COVID-19 (N = 2
patients per group) were obtained from the Pathology
Department of the INER. Sections of 3–5 mm were processed
for hematoxylin–eosin (H&E) staining for histopathological
analysis. For immunohistochemistry (IHQ), lung sections were
mounted on silane-covered slides, deparafﬁnized, and the
endogenous peroxidase blocked. Sections were incubated
overnight at room temperature with an optimal dilution (1:100)
of the Mouse Anti-Human CXCL17/VCC-1 Monoclonal Antibody
(Clone # 422208, MAB4207, R&D Systems, Minneapolis, MN).
Secondary biotinylated antibodies labeled with peroxidase were
added, and those attached were revealed with diaminobenzidine
(ImmunoCruz™ rabbit ABC Staining System, Santa Cruz
Biotechnology, Santa Cruz, CA). Slides were counter-stained
with hematoxylin.

RT-PCR for SARS-CoV-2 Detection
Brieﬂy, viral RNA was extracted from clinical samples with the
MagNA Pure 96 system (Roche, Penzberg, Germany). The RTPCR reactions were performed in a total volume of 25 ml,
containing 5 ml of RNA, 12.5 ml of 2× reaction buffer provided
with the Superscript III one-step RT-PCR system with Platinum
Taq Polymerase (Invitrogen, Darmstadt, Germany; containing
0.4 mM of each deoxyribose triphosphates (dNTP) and 3.2 mM
magnesium sulfate), 1ml of reverse transcriptase/Taq mixture
from the kit, 0.4 ml of a 50 mM magnesium sulfate solution
(Invitrogen), and 1 mg of non-acetylated bovine serum albumin
(Roche). Primer and probe sequences, as well as optimized
concentrations, are shown in Supplementary Table 1. All
oligonucleotides were synthesized and provided by Tib-Molbiol
(Berlin, Germany). Thermal cycling was performed at 55°C for
10 min for reverse transcription, followed by 95°C for 3 min and
then 45 cycles of 95°C for 15 s, 58°C for 30 s.

Ethics Statement
The current study was reviewed and approved by the
Institutional Review Boards of the INER (approval number:
B04-15, B28-16 and B09-20) and the INCMNSZ (approval
number: 3349) in Mexico City. All participants or their legal
guardians provided written consent to participate in the study.
Serum samples were managed according to the Mexican law
NOM-012-SSA3-2012, which establishes the criteria for the
execution of clinical investigations in humans.

In Vitro Infection Assays With Inﬂuenza A
(H1N1) pdm09 Virus

Statistical Analysis
Descriptive statistics were used to characterize the population
under study clinically. Frequencies and proportions were
calculated for categorical data. Means, medians, standard
deviations (SD), interquartile ranges (IQR), and 95%
conﬁdence intervals (CI) were used for continuous variables.
Differences in categorical variables between groups were assessed
by the Fisher exact or Chi-square test, as appropriate. For
comparisons of continuous variables between two groups, we
used the Mann–Whitney U test. For differences of continuous
data between more than two groups, we used the Kruskal–Wallis
test with post hoc Dunn test. Differences in serum levels of
CXCL17 measured in serial samples were determined using the
Wilcoxon matched-pairs signed-rank test. Multiple linear
regression analyses using Spearman rank correlation
coefﬁcients were used to determine correlations between

Inﬂuenza A(H1N1) pdm09 virus was isolated from patients with
severe pneumonia in Madin–Darby canine kidney cells
(MDCK). Virus infectivity was assessed by titration of tissue
culture infection dose 50% (TCID50) in MDCK cells, as
previously described (9). Human lung adenocarcinoma
epithelial cells A549 were purchased from the American Type
Culture Collection (ATCC, Rockville, MD) and cultured in
DMEM with 10% fetal bovine serum (Lonza) at 37°C and 5%
CO2. Human macrophages were obtained and cultured as
described before (9). A549 epithelial cells and macrophages
were infected with inﬂuenza A(H1N1) pdm09 virus at a
multiplicity of infection (MOI) of 5 for one hour. Mocktreated cells received a virus-free culture medium. After
incubation, cells were washed twice with phosphate buffer

Frontiers in Immunology | www.frontiersin.org

3

February 2021 | Volume 12 | Article 633297

Choreño-Parra et al.

CXCL17 in Pandemic Inﬂuenza A(H1N1)

cases. We should note that despite this, COVID-19 patients
showed higher mortality compared to inﬂuenza (41 vs. 23%,
p = 0.1151).
An additional cohort of 30 patients with active PTB were
included in the study. These individuals were sex-matched with
inﬂuenza patients. However, they presented some differences
regarding their clinical and demographic characteristics. First,
PTB patients were younger than inﬂuenza subjects, with a
median age of 38 years. Sixty-six percent were males and
showed a lower body mass index (BMI) than inﬂuenza and
COVID-19 patients. There were no differences in the prevalence
of diabetes between groups. Finally, although PTB showed a
milder and chronic clinical disease with regards to inﬂuenza and
COVID-19, they had high degrees of lung damage according to
their scores in a quantitative scale that evaluates changes on chest
radiographs (data not shown) (10).

continuous clinical variables and serum levels of CXCL17. The
K-means algorithm was used for clustering study participant
characteristics according to their diagnosis (inﬂuenza or
COVID-19) and clinical outcome (survival or fatality). Before
data visualization, clinical features and laboratory parameters
were scaled and centered.
To identify the variables with the highest impact on disease
diagnosis (inﬂuenza, COVID-19) and adverse outcomes (death),
random forest analyses of 500 classiﬁcation and regression trees
(CARTs) were performed. The diagnostic accuracy of serum
CXCL17 levels and other selected variables identiﬁed by random
forest logarithm was further evaluated by bivariate logistic
regression and Receiver Operating Characteristic (ROC) curve
(AUC) analyses. In addition, Kaplan–Meier curves were
constructed to look for differences in survival according to
serum CXCL17 levels dichotomized by the ROC curve
threshold with the highest diagnostic accuracy estimated using
the Youden index. For random forest and logistic regression
analyses, patients with any missing value in the variables of
interest were excluded.
All analyses were conducted using GraphPad Prism 8 (La
Jolla, CA) and R Statistical Software (Foundation for Statistical
Computing, Vienna, Austria). Speciﬁc analytical tests are also
described in the ﬁgure legends. Values of p ≤0.05 were
considered as signiﬁcant: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001,
****p ≤ 0.0001.

Expression of CXCL17 in the Lung of
Patients With Inﬂuenza or COVID-19
CXCL17 is constitutively expressed in the respiratory tract and
lungs of mice and humans (1, 2). Under inﬂammatory
conditions, the production of this chemokine is known to be
further upregulated (2, 4, 5, 11, 12). To investigate whether
CXCL17 may participate in immunity against the inﬂuenza A
(H1N1) virus, we analyzed the tissue expression pattern of
CXCL17 in lung autopsy specimens obtained from patients
who died of inﬂuenza. The histological changes induced in the
lungs during inﬂuenza were mainly characterized by intraalveolar inﬂammatory inﬁltrates consisting of macrophages
and polymorphonuclear cells scattered between areas of edema,
hemorrhage, and ﬁbrin deposits (Figure 1A, left upper panel).
We also noted that the integrity of alveolar walls and the microarchitecture of the lung were conserved in inﬂuenza patients
(Supplementary Figure 1). CXCL17 expression was detected
mainly within the cytoplasm of inﬁltrating macrophages, but not
in polymorphonuclear cells. The expression of CXCL17 was also
detected within alveolar epithelial cells (Figure 1A, left lower
panel). Blood vessels and pleura did not express CXCL17 in lung
autopsy specimens from inﬂuenza patients (data not shown).
We also evaluated the tissue-expression pattern of CXCL17 in
lungs of patients that succumbed to COVID-19. Interestingly, we
found that SARS-CoV-2 induced distinctive morphological
changes in the infected lung, characterized by an intense
inﬂammatory inﬁltrate affecting extensive areas of the
parenchyma, as well as the thickness of alveolar walls, and
partial loss of the histological architecture of the lung
(Supplementary Figure 1 and Figure 1A, right upper panel).
These changes are compatible with interstitial pneumonia. As
observed in inﬂuenza infected lung sections, the expression of
CXCL17 in the lungs of deceased COVID-19 patients was also
detected within macrophages and alveolar epithelial cells (Figure
1A, right lower panel). CXCL17 was not expressed in endothelial
cells of alveolar capillaries, but pleura showed increased CXCL17
expression (data not shown). Collectively, these ﬁndings
demonstrate that CXCL17 can be detected in the lungs during
inﬂuenza and SARS-CoV-2 infection.

RESULTS
Participant Characteristics
A total of 68 patients infected with inﬂuenza were enrolled in the
study. Their clinical characteristics are summarized in Table 1.
Seventy percent of inﬂuenza patients were male, with a median age
of 48 years. We also recruited 24 patients with COVID-19, from
which most were males (75%), with a median age of 50 years. Most
patients with inﬂuenza presented similar characteristics than
COVID-19, except for some speciﬁc differences. For instance,
obesity was more common among inﬂuenza patients, while the
prevalence of other comorbidities did not differ between both
diseases. Cough, dyspnea, fever, myalgia, and arthralgia were the
most frequent symptoms of respiratory illness in both participant
groups. Interestingly, dyspnea, rhinorrhea, and sputum production
were more common during inﬂuenza, whereas dry cough and vomit
were more frequent among COVID-19 patients (Table 1).
Triage vital signs were similar between groups, except for a
higher blood temperature and heart rate in inﬂuenza patients.
Also, most laboratory parameters routinely tested in emergency
departments did not differ between individuals with inﬂuenza
and COVID-19. The levels of aspartate aminotransferase (AST),
lactate dehydrogenase (LDH), alkaline phosphatase (ALP), and
procalcitonin were increased in inﬂuenza patients as compared
to COVID-19 subjects (Table 1). Similarly, severity of illness
scores at admission, including the Sequential Organ Failure
Assessment (SOFA), and the Acute Physiology and Chronic
Health Evaluation II (APACHE-II), were higher in inﬂuenza
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TABLE 1 | Clinical characteristics and laboratory parameters of study participants.
Characteristics
Age (years), median (range)
Males
BMI
Comorbidities
Smoking
Diabetes
SAH
OSA
COPD
Symptoms at onset
Fever
Myalgia
Arthralgia
Headache
Dyspnea
Nasal congestion
Rhinorrhea
Sore throat
Thoracic pain
Cough
Sputum
Dry cough
Fatigue
Diarrhea
Nausea
Vomit
Illness onset - admission (days)
Admission vital signs
Body temperature (°C)
Respiratory rate (bpm)
Hearth rate (bpm)
MAP (mmHg)
Glucose (mg/dl)
Blood count
White blood cells (109/L)
Neutrophils (109/L)
Lymphocytes (109/L)
NLR
Hgb (g/dl)
Platelets (109/L)
Renal function
Cr (mg/dL)
BUN (mg/dl)
Na (mmol/L)
K (mmol/L)
Liver function
Total bilirubin (mg/dl)
AST (U/L)
ALT (U/L)
Other biomarkers
LDH (U/L)
ALP (U/L)
CPK (U/L)
Procalcitonin (ng/ml)
PaO2/FiO2
Severity of illness
SOFA
APACHE II
Respiratory support
High ﬂow nasal cannula
MV
Prone position

Inﬂuenza, N = 68A

COVID-19, N = 24B

p-value, A vs B

PTB, N = 30C

p-value, A vs C

48 (20–77)
48 (70.5)
33.4 (30–38.2)

50 (28–73)
18 (75)
28.9 (25.2–30.3)

0.6536
0.7953
<0.0001

39 (20–46)
20 (66.6)
20.6 (18.8–23.1)

0.0010
0.8126
<0.0001

27 (39.7)
14 (20.5)
18 (26.4)
4 (5.8)
3 (4.4)

5 (20.8)
7 (29.1)
5 (20.8)
0 (0)
1 (4.1)

0.1349
0.4063
0.7848
0.5695
>0.9999

0 (0)
11 (36.6)
2 (6.6)
0 (0)
0 (0)

<0.0001
0.1306
0.0295
0.3095
0.5507

62 (91.1)
56 (82.3)
53 (79.1)
33 (48.52)
65 (95.5)
13 (19.1)
26 (38.2)
24 (35.8)
9 (13.2)
66 (97)
38 (55.8)
27 (40.2)
49 (72)
5 (7.35)
4 (5.88)
2 (2.9)
7.5 (5.2–12)

18 (75)
18 (75)
16 (66.6)
11 (45.8)
16 (66.6)
1 (4.1)
3 (12.5)
4 (16.6)
0 (0)
21 (87.5)
2 (8.3)
19 (79.1)
18 (75)
5 (20.8)
3 (12.5)
4 (16.6)
6 (4.2–10.7)

0.0725
0.5500
0.2847
>0.9999
0.0007
0.1038
0.0221
0.1223
0.1053
0.1093
<0.0001
0.0017
>0.9999
0.1196
0.3717
0.0382
0.3756

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–

38 (37–38)
25 (20–30)
96 (85-108)
85.4 (75–118.3)
144.9 (114.9–221.4)

37 (37–37.08)
24 (22–26)
85 (75–96)
77.5 (71–87)
115.6 (96.7–200.7)

0.0018
0.3486
0.0074
0.0677
0.0771

–
–
–
–
–

–
–
–
–
–

7.2 (5.6–10.3)
5.7 (4.5–8.3)
0.8 (0.5–1.1)
8.5 (5.4–12.6)
14.9 (13.3–17.3)
177.5 (136.5–216.5)

9.1 (5.2–12.2)
7.4 (3.6–10.1)
0.8 (0.6–1.0)
8.7 (3.9–13.4)
14.1 (13.2–15.3)
202 (145.8–256.8)

0.4429
0.7057
0.4657
0.7927
0.1015
0.2523

–
–
–
–
–
–

–
–
–
–
–
–

1.02 (0.7–1.4)
24.9 (15.5–35.7
137.4 (133.4–140.5)
4.1 (3.8–4.5)

1.0 (0.8-1.4)
18.3 (13.6-26.8)
138.6 (136-141.5)
4.1 (3.9-4.3)

0.8754
0.1390
0.2155
0.9384

–
–
–
–

–
–
–
–

0.6 (0.4–0.8)
61.8 (44.7–87)
41 (26.3–52.2)

0.4 (0.3-0.7)
35.1 (23.6-80.7)
32.7 (25.1-48.4)

0.0900
0.0055
0.2768

–
–
–

–
–
–

643.8 (500–877.9)
121.7 (98.2–161.1)
274.4 (108–700.8)
0.55 (0.15–1.92)
82.5 (59.9–143.5)

341.7 (251.5-477.7)
78 (67.7-88.2)
117.8 (64-117.8)
0.1 (0.05-0.17)
127.8 (94.7-198.1)

<0.0001
<0.0001
0.4754
<0.0001
0.0031

–
–
–
–
–

–
–
–
–
–

7 (5–9)
10 (7–16)

5 (3-6)
7 (4-8)

0.0002
0.0069

–
–

–
–

0 (0)
68 (100)
40 (58.8)

7 (29.1)
17 (70.8)
8 (33.3)

<0.0001
<0.0001
0.0359

0 (0)
0 (0)
0 (0)

>0.9999
<0.0001
<0.0001
(Continued)
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TABLE 1 | Continued
Characteristics

Inﬂuenza, N = 68A

COVID-19, N = 24B

p-value, A vs B

PTB, N = 30C

p-value, A vs C

7 (10.2)
16 (23.5)
16 (23.5)

0 (0)
2 (8.3)
10 (41.6)

0.1836
0.1399
0.1151

0 (0)
0 (0)
0 (0)

0.1836
0.0022
0.0022

ECMO
Renal replacement therapy
Mortality

Data are displayed as n (%) or median (IQR). N is the total number of patients with available data. ALP, alkaline phosphatase; APACHE-II, Acute Physiology And Chronic Health Evaluation II;
AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMI, body mass index; bpm, breaths/beats per minute; BUN, blood ureic nitrogen; COPD, chronic obstructive
pulmonary disease; CPK, creatine phosphokinase; Cr, creatinine; ECMO, extra-corporeal membrane oxygenation; FiO2, fraction of inspired oxygen; HCO3, bicarbonate; Hgb,
hemoglobin; IQR, interquartile range; ICU, intensive care unit; LDH, lactate dehydrogenase; MAP, mean arterial pressure; MV, mechanical ventilation; ND, not determined; NLR, neutrophil/
lymphocyte ration; OSA, obstructive sleep apnea syndrome; PaO2, partial pressure of oxygen in arterial blood; PCO2, partial pressure of carbon dioxide in blood; SAH, systemic arterial
hypertension; SD, standard deviation; SOFA, Sequential Organ Failure Assessment. Differences in continuous variables were estimated using the Mann–Whitney U test. Differences in
categorical variables were calculated using the Fisher’s exact or the Chi square test as appropriate.

identiﬁed in the random forest algorithm, only CXCL17, along
with procalcitonin, showed signiﬁcant association with inﬂuenza
(Supplementary Figure 2). LDH and ALP were marginally
associated with inﬂuenza, whereas platelets showed no correlation
with any type of infection. Interestingly, although irrelevant in the
random forest algorithm, symptoms such as dyspnea, rhinorrhea,
and sputum production were predictors of inﬂuenza, whereas dry
cough and vomit were associated with COVID-19.
To further estimate the diagnostic value of CXCL17, we
performed a ROC curve analysis with the serum levels of
CXCL17 of inﬂuenza and COVID-19 subjects. We observed that
CXCL17 levels could reliably differentiate between inﬂuenza and
COVID-19, with an AUC of 0.81 (Figure 1E). Using a cut-off
value of 841 pg/ml, elevated serum levels of this chemokine have a
78.2% sensitivity, 73.5% speciﬁcity, 89.2% PPV, 51.3% NPV, and
an OR of 8.79 (3.1–26, 95% CI) to distinguish inﬂuenza from
COVID-19. Together, our results point to the diagnostic use of
serum CXCL17 levels in patients with acute respiratory illness to
enable distinguishing infection between these viruses, although
these ﬁndings must be validated in larger cohorts of patients, as
well as in patients infected with seasonal inﬂuenza viruses.

High Serum Levels of CXCL17 Distinguish
Inﬂuenza From Other Respiratory Infections
Although CXCL17 is mainly produced at mucosal surfaces,
increased serum levels of this chemokine might serve as a readout
of active local immune responses. Thus, we addressed whether the
CXCL17 expression found in the lungs of inﬂuenza- and SARSCoV-2-infected patients could be also detected in the serum. Our
results indicate that CXCL17 levels were signiﬁcatively elevated in
the serum of inﬂuenza cases, but not in healthy donors (HD) or
COVID-19 subjects. The latter group indeed showed low serum
CXCL17 levels, similar to the levels observed in HD (Figure 1B).
These ﬁndings contrast with the expression of CXCL17 detected in
the lung of COVID-19 patients, suggesting that the levels of
CXCL17 in serum and its expression in lung tissue specimens do
not correlate during the course of the disease. Nonetheless, our lung
immunohistochemical analyses only focused on the expression of
this chemokine in the late stages of inﬂuenza and COVID-19,
whereas serum samples were taken within the ﬁrst day after
patients´ hospital admission. We also measured the levels of
CXCL17 in serum samples from PTB patients. Notably, we found
that the levels of the chemokine in PTB individuals were much
lower compared to those observed in inﬂuenza patients (Figure 1B).
In contrast, no differences in serum CXCL17 levels were observed
between COVID-19 and PTB patients. These ﬁndings suggest
distinctive serum CXCL17 dynamics during inﬂuenza, COVID19, and PTB that could potentially be harnessed for diagnostic
purposes. This is important since inﬂuenza and COVID-19 will
converge at some point during the ongoing winter in the North
Hemisphere. As such, physicians will require novel rapidly testable
diagnostic biomarkers to discriminate both diseases, specially at
setting of limited availability of RT-PCR tests.
Hence, next we investigated if CXCL17, along with other clinical
characteristics, could have certain diagnostic value to discriminate
between both viral infections. In an unsupervised clustering analysis,
we found that some inﬂuenza patients grouped together according
to their clinical and laboratory parameters, but another cluster was
formed by combined inﬂuenza and COVID-19 subjects (Figure
1C). This suggests that the differentiation of the two infections by
clinical characteristics would be difﬁcult in the emergency room.
Nonetheless, in a random forest analysis, CXCL17 was among the
most explicative variables of the viral subtype (Figure 1D). Indeed,
in a bivariate logistic regression analysis using the variables
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Dynamics and Prognostic Value of Serum
CXCL17 Levels in Inﬂuenza
Next, we evaluated the dynamics of serum CXCL17 levels during
inﬂuenza. For this purpose, we grouped inﬂuenza patients
according to the duration of their illness, deﬁned as the period
from symptom onset to hospital admission. Interestingly, we found
that levels of CXCL17 increased early in inﬂuenza patients within
the ﬁrst two days following the onset of symptoms, and levels
remained increased during the ﬁrst two weeks of illness. However,
the maximum levels of CXCL17 were observed among inﬂuenza
patients seeking medical attention three weeks after the onset of
symptoms (Figure 2A). In 54 of the 68 inﬂuenza patients enrolled
in the study, an additional serum sample was obtained seven days
(D7) following hospital admission (D0). Although there were no
differences in CXCL17 between D0 and D7, most patients showed
constant or decreasing chemokine levels (Figure 2B), except for
one individual who showed a notable increase in CXCL17 and
succumbed to the infection. Overall, the dynamics of CXCL17
levels post-hospital admission were similar in survivors and
deceased inﬂuenza patients (Figure 2C).
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A
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E
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FIGURE 1 | CXCL17 in the lung and serum of inﬂuenza, COVID-19, and PTB patients. (A) Morphological changes observed in the lung of inﬂuenza and COVID-19
patients (n = 2 per group). H&E, ×400. The expression of CXCL17 was analyzed in lung autopsy specimens from inﬂuenza (left lower panel) and COVID-19 (right
lower panel). IHQ, ×400. (B) Serum CXCL17 levels in healthy donors (HD; n = 30) patients with inﬂuenza (n = 68), COVID-19 subjects (n = 24), and PTB patients
(n = 30). Kruskal–Wallis test and post hoc Dunn test (plots display medians with interquartile ranges; ****p ≤ 0.0001). (C) K-means clustering analysis of the clinical
characteristics of inﬂuenza and COVID-19 patients. (D) Random forest algorithm showing the most important factors that differentiate inﬂuenza from COVID-19. The
points represent the mean decrease Gini values, indicative of the importance of each variable with respect to the mean importance of the model (discontinuous
vertical line). (E) Receiver operating characteristic (ROC) curve of the levels of CXCL17 in inﬂuenza and COVID-19 subjects. The graph displays area under the curve
(AUC) and 95% CI interval values.

Most clinical and laboratory parameters did not differ between
the two groups of inﬂuenza patients (Supplementary Table 2).
Furthermore, none of these clinical characteristics impacted the
serum levels of CXCL17 (Figure 3A), and this chemokine was not
associated with the severity of ARDS in terms of the PaO2/FiO2
values at admission (Figure 3B). These results together suggest that
CXCL17 represents an independent prognostic factor for mortality
in inﬂuenza. In contrast, no differences in serum CXCL17 levels at
admission were observed between survivor- and deceased-COVID19 patients (Figure 3C), and this chemokine showed no correlation
with the lung damage score of patients with PTB (Supplementary
Figure 3).
We also noted that CXCL17 was increased among inﬂuenza
patients that developed acute kidney injury (AKIN; Figure 3D),
and its levels were even higher in individuals requiring renal

Importantly, serum levels of CXCL17 at D0 were signiﬁcatively
higher in patients who died of inﬂuenza as compared to survivors
(Figure 2D). Indeed, CXCL17 again was among the variables with
the higher importance for inﬂuenza-associated mortality in a
random forest analysis (Figure 2E), showing an AUC of 0.70 to
differentiate both groups in the ROC curve analysis (Figure 2F).
Serum levels of CXCL17 above 1,128 pg/ml predicted a fatal
outcome with a 75% sensitivity and 50% speciﬁcity, showing a
non-signiﬁcant OR value for mortality of 3.0 (0.86–9.24, 95% CI).
The survival of patients with CXCL17 below such cut-off value
was lower at day 14 after admission when compared to individuals
with higher levels of this chemokine (Figure 2G, Table 2).
Conversely, accumulated survival at days 28 and 60 following
hospital admission was lower in inﬂuenza patients with serum
levels of CXCL17 ≥1,128 pg/ml.
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FIGURE 2 | Dynamics and prognostic value of serum CXCL17 levels in inﬂuenza (A) Inﬂuenza patients (n = 68) were grouped according to their duration of
symptoms on admission. Levels of CXCL17 were compared to healthy donors (HD; Kruskal–Wallis test and post hoc Dunn test; graph displays means and the
standard error ( ± SE); *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001). (B) We obtained a second serum sample in 54 inﬂuenza subjects seven days (D7) after
hospital admission (D0). Levels of CXCL17 at D0 and D7 were compared with the Mann–Whitney U test. (C) Longitudinal change in CXCL17 levels in survivor and
deceased inﬂuenza patients (Wilcoxon test). (D) Initial serum CXCL17 levels in survivor (n = 52) and deceased (n = 16) inﬂuenza patients (Mann–Whitney U test; plots
display medians and interquartile ranges). (E) Random forest algorithm showing the most important factors that impact on inﬂuenza-associated mortality.
(F) Receiver operating characteristic (ROC) curve of the levels of CXCL17 in survivor and deceased inﬂuenza subjects. The graph displays area under the curve
(AUC) and 95% CI interval values. (G) Survival curves of inﬂuenza patients grouped according to their serum CXCL17 levels were compared with the log-rank test.

replacement therapy (Figure 3E). Using the same cut-off value of
1,128pg/mL, elevated serum levels of CXCL17 showed a 73.6%
sensitivity, 51% speciﬁcity, and a non-signiﬁcant OR of 2.91 (0.96–
8.28, 95% CI) to predict the development of AKIN (Figure 3F).
Similarly, increased levels of CXCL17 showed an 87.5% sensitivity,
53.8% speciﬁcity, and a signiﬁcant OR of 8.16 (1.71–38, 95% CI) to
predict the need for renal replacement therapy (Figure 3G).

pdm09 virus. Interestingly, while both human cell types produced
high amounts of CXCL17 at 24 h, 48h, and 72h after the infection,
A549 epithelial cells produced lower levels of CXCL17 in response
to inﬂuenza as compared to macrophages (Figures 3H, I). These
ﬁndings are consistent with the expression of CXCL17 in lung
macrophages and alveolar epithelial cells in autopsy specimens
from our inﬂuenza patients. This suggests that the inﬂuenza A
(H1N1) pdm09 virus stimulates CXCL17 expression in humans,
both in vivo and in vitro. However, further analyses are required to
conﬁrm a role for CXCL17 in inﬂuenza.

Inﬂuenza A(H1N1) pdm09 Virus Induces
the Production of CXCL17 in Human Lung
Epithelial Cells and Macrophages
The higher levels of CXCL17 in sera from inﬂuenza patients
prompted us to investigate the possible cellular sources of CXCL17
during inﬂuenza. To this end, we infected human A549 lung
alveolar epithelial cells and peripheral blood monocyte-derived
macrophages with a clinical isolate of the inﬂuenza A(H1N1)
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The clinical spectrum of ARDS encompasses very severe forms of
the disease characterized by a profound respiratory failure. These
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TABLE 2 | Cumulative survival rates in patients with inﬂuenza according with
their serum CXCL17 levels.
Time after hospital
admission

Thus, particular immune proﬁles of local and circulating
cytokines may serve as readouts to differentiate between speciﬁc
causes of ARDS. Here, we demonstrate that CXCL17 can be
detected in post-mortem human lung specimens from patients
with pandemic inﬂuenza A(H1N1) and COVID-19. Furthermore,
serum levels of CXCL17 are differentially regulated during
inﬂuenza and COVID-19, pointing to a possible diagnostic
value for the chemokine. Importantly, we found that CXCL17 is
not elevated in the serum of PTB patients neither. Although
individuals with this disease rarely present with ARDS, the fact
that only inﬂuenza but not PTB or COVID-19 patients showed
high CXCL17 levels remarks the speciﬁc diagnostic potential of
this chemokine during inﬂuenza.
Chemokines can be divided into homeostatic or inﬂammatory
depending on their expression patterns (13). CXCL17 is considered
a “dual” chemokine because it exhibits characteristics of both

Survival (%, 95% CI)

7 days
14 days
21 days
28 days
60 days

CXCL17 <1,128 pg/ml

CXCL17 ≥ 1,128 pg/ml

96.66 (78.6–99.52)
84.86 (64.38–94.06)
84.86 (64.38–94.06)
84.86 (64.38–94.06)
84.86 (64.38–94.06)

94.73 (80.55–98.65)
91.776 (76.56–97.27)
85.06 (67.5–94.16)
63.33 (41.48–78.89)
31.66 (1.93-71.53)

Survival rates and their 95% CI were estimated using the Kaplan-Meyer method and the
log rank test.

manifestations are often related to dysregulated immune reactions
elicited by different insults. The quality and magnitude of such
responses may vary according to the causative agent of the illness.

A

B

C

E

D

F

G

H

I

FIGURE 3 | Extended predictive value of serum CXCL17 levels in inﬂuenza patients and cellular sources. (A) Multiple correlation analysis of the clinical variables and
serum CXCL17 levels of inﬂuenza patients (n = 68). The heat color map gradient was constructed using Spearman R values. (B) Serum CXCL17 levels in inﬂuenza
patients according to the severity of their acute respiratory distress syndrome (ARDS) on admission (mild, PaO2/FiO2 >200, n = 3; moderate, PaO2/FiO2 100–200,
n = 27; severe, PaO2/FiO2 <100, n = 38; Kruskal–Wallis test and post hoc Dunn test). (C) Comparison of the levels of CXCL17 between COVID-19 patients that
survived (n = 14) or died (n = 10). Mann–Whitney U test. (D) Serum levels of CXCL17 were compared between inﬂuenza patients that developed acute kindly injury
(AKIN, n = 19), and individuals with normal renal function (n = 49). (E) Differences in CXCL17 levels between inﬂuenza patients according to their need for renal
replacement therapy (RRT; n = 52 vs 16). (B–E) Plots display medians and interquartile ranges. Mann–Whitney U test. (F) Receiver operating characteristic (ROC)
curve of the CXCL17 levels in inﬂuenza patients that developed AKIN and those that maintained normal renal function. The graph display area under the curve (AUC)
and 95% CI interval values. (G) ROC curve analysis of the serum CXCL17 levels in patients requiring RRT. (H) Human A549 alveolar epithelial cells and (I) peripheral
blood-monocyte derived macrophages were infected with a clinical isolate of the inﬂuenza A(H1N1) pdm09 virus for 24, 48, and 72 h n = 6–7 per group per time
point). Levels of CXCL17 in supernatants from infected and uninfected cells were compared using the unpaired Student’s t test (n = 5 to 9 per group) at each time
point. Values of p were corrected for multiple comparisons using the Holm–Sidak method. The data represent mean ( ± SE) values from 2 to 3 independent
experiments per time point and experimental condition. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
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could have a prognostic value in COVID-19 should be investigated
in future studies.
Our ﬁndings may be also explained by possible different abilities
of inﬂuenza and SARS-CoV-2 virus strains to induce local CXCL17
production and translocation to the blood according to their
virulence. Indeed, previous research showed that the infection of
human bronchial epithelial cells, human tracheobronchial epithelial
cells, and human alveolar A549 cells with seasonal inﬂuenza A
(H3N2) virus, promotes robust upregulation of CXCL17. However,
the infection with more virulent A(H5N1) and A(H7N9) inﬂuenza
virus subtypes induces minor changes in the expression of CXCL17
(18). Similarly, in a yet unpublished experiment available from the
Inﬂuenza Research Database (IRD), the infection of 2B-4cells/
sorted Calu-3 cells with a wild type strain of the 2002-2003
SARS-CoV (icSARS CoV) did not stimulate strong expression of
CXCL17 (19). In contrast, the infection with icSARS ExoNI and
icSARS dNSP16, which are attenuated mutant strains of SARSCoV, upregulated the expression of CXCL17.
Notably, we also demonstrated that these differences could be
harnessed for clinical applications, as serum CXCL17 levels
determined at hospital admission are useful to distinguish
between inﬂuenza and COVID-19 in patients with ARDS. This
is important, especially at settings of high circulation of
pandemic inﬂuenza A(H1N1) virus strains, as it is highly likely
that both diseases will converge during the upcoming ﬂu season.
During such a predicted scenario, the differentiation of inﬂuenza
and COVID-19 by clinical characteristics may be complicated.
Indeed, our results and previous studies show that only a few
non-speciﬁc symptoms and routine laboratory tests are useful for
this diagnostic dilemma (20–22). However, the discrimination of
the causative pathogen has direct therapeutic implications,
including the selection of the adequate anti-viral drug. Thus,
novel biomarkers with high diagnostic value to distinguish
inﬂuenza and COVID-19 are urgently needed.
Another striking ﬁnding of our study is that serum levels of
CXCL17 impact on pandemic inﬂuenza A(H1N1)-associated
mortality. In this sense, it is known that several chemokines
participate in the immune response against inﬂuenza viruses (23,
24). Most of them are produced in high amounts and mediate
pathology due to their pro-inﬂammatory properties (25, 26). Our
data indicate that the production of CXCL17 is also highly
potentiated during the early stages of pandemic inﬂuenza A
(H1N1), as the serum levels reported here are as high as those
found in other inﬂammatory and human autoimmune disorders
(2, 11). Moreover, we demonstrate that both macrophages and
lung epithelial cells can become sources of CXCL17 after
infection with the inﬂuenza A(H1N1) pdm09 virus.
CXCL17 normally mediates the recruitment of myeloid cells to
the lung (4). Cell subtypes responding to this chemokine include
DCs, monocytes, and macrophages (1, 4, 27). However, we should
note that the nature of the myeloid cells recruited by CXCL17 in vivo
has not been established in humans, although the fact that CXCL17
is a mucosal chemokine expressed only in the respiratory and
digestive tracts suggests that it is recruiting unique population(s) of
myeloid cells to mucosal tissues which remain to be functionally
characterized. Increased and sustained recruitment of myeloid cells

homeostatic and inﬂammatory chemokines. It is constitutively
expressed in the mucosa of the respiratory tract with potential
functions in lung defenses (14) and is known to chemoattract
macrophages (4). This chemokine was the last member of the C-XC motif chemokine ligand family to be reported (1), and as such, its
role during respiratory inﬂammation or infections is not well
understood. We should note that bioinformatics analyses of
public gene expression databases indicate that CXCL17 is the
highest expressed chemokine in the normal trachea and
bronchus and among the highest expressed chemokines in the
normal human lung (2). These observations strongly suggest
important homeostatic functions for CXCL17 in the respiratory
tract. Previous studies have shown that CXCL17 is strongly
upregulated in idiopathic pulmonary ﬁbrosis (2). This, along
with data from our current study indicates that CXCL17 is very
likely to have important functions in the pathogenesis of
inﬂammatory/infectious diseases of the lung as well. Past studies
have provided indirect evidence about a possible role of CXCL17 in
immunity against respiratory infections. For instance, it has been
shown that CXCL17 has a potent bactericidal activity over bacteria
causative of respiratory infections (2). The expression of the
CXCL17 gene was also found upregulated in group 3 innate
lymphoid cells isolated from lung tissues of patients with
tuberculosis (TB) (15), suggesting a role for CXCL17 against
Mycobacterium tuberculosis (Mtb) infection. However, CXCL17
plays redundant activities during anti-Mtb immunity in murine
models (16). In this context, our study represents the ﬁrst direct
evaluation of the expression of CXCL17 during respiratory
infections in humans.
Our analyses of lung autopsy specimens suggest that the
inﬂuenza A(H1N1) pdm09 virus and SARS-CoV-2 stimulate
the local production of CXCL17 in the pulmonary tissue. Indeed,
although these ﬁndings were made only in two patients who died
of inﬂuenza and two with COVID-19, the pattern of expression
observed during both infections differ from what it is observed at
steady state. In this regard, using non-infected human lung
specimens, we previously demonstrated that CXCL17 is
detected only at the luminal surface of alveolar epithelial cells
(2). Conversely, here we found that lungs infected with inﬂuenza
and SARS-CoV-2 express CXCL17 in the whole cytoplasm of
pneumocytes, as well as in inﬁltrating macrophages. This is further
supported by a recent paper demonstrating a high induction of
CXCL17 in the BAL of COVID-19 (17). However, we found that
the magnitude of CXCL17 expression in the serum was also robust
during inﬂuenza but minimal in COVID-19 patients. These are
contrasting observations, although we must consider that the lung
tissue specimens in our study were obtained post-mortem.
Therefore, our immunohistochemical analysis evaluated the
expression of CXCL17 only during the latest phases of viral
infection, whereas serum chemokine determinations captured
early responses against COVID-19 and inﬂuenza. Analysis of
CXCL17 expression in lung biopsy specimens obtained early
during the infection would have clariﬁed this point. Despite this,
we speculate that lung and serum CXCL17 levels may increase as
the infection with SARS-CoV-2 progresses in patients with severe
disease. Whether longitudinal changes in serum CXCL17 levels

Frontiers in Immunology | www.frontiersin.org

10

February 2021 | Volume 12 | Article 633297

Choreño-Parra et al.

CXCL17 in Pandemic Inﬂuenza A(H1N1)

to the lungs is associated with immunopathology and mortality in
inﬂuenza (23, 24). Accordingly, our data indicate that inﬂuenza
patients with higher CXCL17 levels have lower survival, suggesting a
possible pathogenic role for this chemokine. We should also mention
that CXCL17 also mediates anti-inﬂammatory activities (25, 26).
Thus, our ﬁndings may reﬂect a regulatory mechanism for the
cytokine storm underlying severe inﬂuenza, via the production of
high levels of anti-inﬂammatory mediators.
The role of innate immune cells responding to CXCL17 in
COVID-19 is unknown, but recent studies have found that the
numbers of circulating DCs and monocytes are reduced in
patients with severe SARS-CoV-2 infection as compared to
patients with milder forms of the disease (28). In contrast, we
found a high number of macrophages in the lung autopsy
specimens of patients that died of COVID-19. Together, these
data point to a possible role for chemokines involved in the
recruitment of myeloid cells to the lungs during COVID-19, and
CXCL17 is an excellent candidate to mediate this recruitment (4).
However, whether CXCL17 plays a pathogenic or protective role
during inﬂuenza or COVID-19 is not apparent from our data.
A caveat of our study is that CXCL17 levels were assessed only
in inﬂuenza patients with severe pandemic inﬂuenza A(H1N1),
but not in individuals with milder forms of the disease nor in
persons with seasonal inﬂuenza infections. Hence, future studies
must validate our results in other cohorts of inﬂuenza patients.
Also, we measured serum levels of CXCL17 in COVID-19
patients only at the time of hospital admission. Thus, the
analysis of additional time points is required to draw
conclusions on the prognostic role of this chemokine in
COVID-19. Finally, our ﬁndings in PTB patients indicate that
CXCL17 is not highly released from the lung to the serum during
Mtb infection. This, along with previous results from our group
(16), may indicate a minimal role for this chemokine during
PTB. Nonetheless, more studies are necessary to rule out a
contribution of CXCL17 to the immunity against Mtb.
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Tecnoló gico y de Innovació n (FORDECYT). JC-P was supported by
a scholarship (CVU 737347) from CONACyT to his Ph.D. degree.
Funders did not play any role in the study design and conduction.

CONCLUSIONS
In conclusion, our study provides preliminary evidence supporting a
diagnostic potential of CXCL17 to distinguish severe pandemic
inﬂuenza A(H1N1) from COVID-19 and other respiratory
infections like PTB. In addition, we show that this chemokine may
be useful as a prognostic biomarker in inﬂuenza patients, as serum
levels of CXCL17 are associated with higher risk of renal failure and
mortality. Finally, we found some possible cellular sources of
CXCL17 during inﬂuenza. Future studies are required to better
understand the function of this chemokine in lung defenses against
the inﬂuenza A(H1N1) pdm09 virus and better evaluated a possible
participation in immunity against SARS-CoV-2.
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Zlotnik and Zúñiga. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal is
cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.

12

February 2021 | Volume 12 | Article 633297

